Does the CD33 rs3865444 Polymorphism Confer Susceptibility to Alzheimer's Disease?


Journal

Journal of molecular neuroscience : MN
ISSN: 1559-1166
Titre abrégé: J Mol Neurosci
Pays: United States
ID NLM: 9002991

Informations de publication

Date de publication:
Jun 2020
Historique:
received: 23 12 2019
accepted: 05 02 2020
pubmed: 24 2 2020
medline: 23 1 2021
entrez: 24 2 2020
Statut: ppublish

Résumé

Alzheimer's disease (AD) is a complex genetic disorder. To date, published data have reported conflicting results on the role of CD33 rs3865444 polymorphism in AD. The present study aimed at evaluating the effect of rs3865444 on AD in a large cohort of Greek native patients with AD. We also conducted a meta-analysis by pooling information from different studies on the same topic. Patients with AD (n = 327) and healthy controls (n = 327) were analyzed and genotyped for rs3865444. Single locus analyses were run to explore possible associations between CD33 rs3865444 polymorphism and AD. Our analysis yielded no significant interaction between AD and the CD33 rs3865444 polymorphism. The lack of interaction between the two variables persisted even after a pooled meta-analysis of 8 studies (with 13 datasets), with 4015 AD cases and 7981 controls. The overall results do not support the hypothesis that CD33 rs3865444 polymorphism increases the risk of AD. The results also suggest that the identification of functional variants in CD33 that are indisputably correlated with AD may be an important factor to investigate in future genetic screening studies.

Identifiants

pubmed: 32088842
doi: 10.1007/s12031-020-01507-w
pii: 10.1007/s12031-020-01507-w
doi:

Substances chimiques

Sialic Acid Binding Ig-like Lectin 3 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

851-860

Subventions

Organisme : This study was supported in part by a research grant from the Research Committee of the University of Thessaly, Greece (code: 5287).
ID : 5287

Auteurs

Vasileios Siokas (V)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Paraskevi Aslanidou (P)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Athina-Maria Aloizou (AM)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Eleni Peristeri (E)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Polyxeni Stamati (P)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Ioannis Liampas (I)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Stylianos Arseniou (S)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.

Nikolaos Drakoulis (N)

Research Group of Clinical Pharmacology and Pharmacogenomics, Faculty of Pharmacy, School of Health Sciences, National and Kapodistrian University of Athens, 15771, Zografou, Greece.

Michael Aschner (M)

Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, 10463, USA.

Aristidis Tsatsakis (A)

Laboratory of Toxicology, School of Medicine, University of Crete, 71003, Heraklion, Greece.

Panayiotis D Mitsias (PD)

Department of Neurology, School of Medicine, University of Crete, 71003, Heraklion, Greece.

Dimitrios P Bogdanos (DP)

Department of Rheumatology and Clinical Immunology, University General Hospital of Larissa, Faculty of Medicine, School of Health Sciences,, University of Thessaly, Viopolis, 40500, Larissa, Greece.

Georgios M Hadjigeorgiou (GM)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece.
Department of Neurology, Medical School, University of Cyprus, Nicosia, Cyprus.

Efthimios Dardiotis (E)

Department of Neurology, Laboratory of Neurogenetics, Faculty of Medicine, University of Thessaly, University Hospital of Larissa, Biopolis, Mezourlo Hill, 41100, Larissa, Greece. edar@med.uth.gr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH